Irish MedTech firm Innovation Zed signs major contract for Bluetooth insulin pen

  • Irish medtech company Innovation Zed has signed a new global partnership with Bulgarian firm SIRMA Medical Systems thanks to its bluetooth-enabled insulin pen.

    One of the most common problems insulin-dependent diabetic people have in treating their condition is poor adherence to a strict schedule. It's been shown that motivating people to adhere to a daily injection routine can significantly improve long-term outcomes, and people use a variety of platforms and daily reminder systems to keep on top of their routines.

    Irish MedTech company Innovation Zed based in NovaUCD at University College Dublin aims to help with that problem with the release of its InsulCheck Connect technology last year. The insulin pen add-on automatically collects usage data and informs insulin pen users of their injection history, and it can connect to any bluetooth-enabled device to show users behavioural analysis on several different platforms.

    The company has now announced that it's signed a global partnership and data integration agreement with SIRMA Medical Systems, part of the massive SIRMA Group of privately owned Bulgarian IT firms. SIRMA Medical Systems produces software applications and integrated health platforms, including the Diabetes:M mobile application for Android and iOS devices.

    The partnership will see the two companis join forces to integrate their products together into a single integrated system that will help keep insulin-dependent diabetic people on target with their medication schedule.

    Innovation Zed Director of Business Development Dean Minnock commented on the deal: "Now that our InsulCheck Connect technology is incorporated with the Diabetes:M platform, we can empower existing platform users, and entice new users to adopt this technology ecosystem with aims to improve adherence and their diabetes treatment."

    Rossen Varbanov, CEO of SIRMA Medical Systems, said: "This global partnership is yet another cornerstone in our strategy to bring quality diabetes management to a wider audience. Therapy adherence is a serious issue and we are dedicated to making a cumbersome task as easy as it could be. The unique features for insulin pen users in Diabetes:M are designed to both save time and allow them to do things, otherwise only available to pump users."

    Source: Written based on press release

    About the author

    Brendan is a Sync NI writer with a special interest in the gaming sector, programming, emerging technology, and physics. To connect with Brendan, feel free to send him an email or follow him on Twitter.

    Got a news-related tip you’d like to see covered on Sync NI? Email the editorial team for our consideration.

Share this story